This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	Ribosomal protein S6 kinase (RSK)	<i>In vitro</i> studies identified an RSK inhibitor that could help treat type 1 diabetes. In mouse α cells, low micromolar concentrations of the RSK inhibitor increased β cell-like morphology, expression of β cell markers and insulin production compared with solvent control. In primary human pancreatic islets, the inhibitor increased glucose-stimulated insulin secretion and expression of endocrine-related genes compared with solvent. Next steps could include determining the mechanism of the inhibitor's effects on human islets.	Patent and licensing status unavailable	Fomina-Yadlin, D. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Aug. 9, 2010; doi:10.1073/pnas.1010018107 Contact: Stuart L. Schreiber, Harvard University, Cambridge, Mass. e-mail: stuart_schreiber@harvard.edu
SciBX 3(32); doi:10.1038/scibx.2010.988				
Published online Aug. 19, 2010				